Oncorena is a pharmaceutical company developing a first-in-class, kidney-specific therapy for patients with advanced kidney cancer. The company’s lead drug candidate, ONC175, is a synthetically produced form of orellanine based on research from the University of Gothenburg, led by Professors Börje Haraldsson and Jenny Nyström. The compound has a unique, kidney-selective mechanism of action, enabling targeted cytotoxicity within renal tissue.
ONC175 is being developed for patients with metastatic renal cell carcinoma who are dependent on dialysis, an underserved population with significant unmet medical need. By enabling an organ-directed chemotherapy approach, the therapy has the potential to offer a novel treatment paradigm in kidney cancer.
The program is currently being evaluated in an ongoing Phase I/II clinical study (Oncorella-1), with multiple active sites across the US and Europe and continued patient enrollment.
